within Pharmacolibrary.Drugs.ATC.C;

model C09BA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 1.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This medicine is a fixed-dose combination of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and a diuretic (typically hydrochlorothiazide). It is approved for the treatment of hypertension (high blood pressure) to reduce blood pressure and manage conditions associated with cardiovascular risk. Both components are well-established and widely used as prescription antihypertensive agents.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy individuals due to the lack of direct combination PK literature. Parameters are based on known PK of lisinopril (oral, adult, healthy volunteers) and, if combined with hydrochlorothiazide, based on their individual properties, noting that fixed-combination does not affect their core PK significantly.</p><h4>References</h4><ol><li><p>Beermann, B (1988). Pharmacokinetics of lisinopril. <i>The American journal of medicine</i> 85(3B) 25–30. DOI:<a href=&quot;https://doi.org/10.1016/0002-9343(88)90346-4&quot;>10.1016/0002-9343(88)90346-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2844083/&quot;>https://pubmed.ncbi.nlm.nih.gov/2844083</a></p></li><li><p>Laher, MS, et al., &amp; Swaisland, AJ (1991). The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. <i>Journal of human hypertension</i> 5 Suppl 2 77–84. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1665183/&quot;>https://pubmed.ncbi.nlm.nih.gov/1665183</a></p></li><li><p>Yang, Z, et al., &amp; He, Y (2024). Pharmacokinetic and Bioequivalence Study of Lisinopril/Hydrochlorothiazide Tablet Under Fasting and Postprandial Conditions in Healthy Chinese Subjects. <i>Clinical pharmacology in drug development</i> 13(2) 160–167. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1329&quot;>10.1002/cpdd.1329</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37718674/&quot;>https://pubmed.ncbi.nlm.nih.gov/37718674</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09BA03;
